Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 6Abiraterone Acetate 6olaparib 5Docetaxel 5darolutamide 4Prednisone 4Pluvicto 4cabazitaxel 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2fludarabine 2abiraterone 2Prednisolone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-resistant Prostate Cancer × ebastine × Clear all
NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Rigshospitalet, Denmark

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡